Is Novo Nordisk a Better Investment Than Eli Lilly?

Eli Lilly & Co has undoubtedly been a highly successful pharmaceutical company, generating significant wealth for investors over the years. However, with its stock trading at a high valuation and much of its growth potential already priced in, investors might be looking for alternative opportunities. Enter Novo Nordisk, a company positioned to outperform Eli Lilly and capitalize on a hot growth trend in the healthcare industry.

While Eli Lilly remains a formidable player in the pharmaceutical sector, the current concern lies in the stock's valuation. Trading at 90 times its forward earnings, the upside potential may be limited. Although the company boasts promising products such as Mounjaro, Zepbound, and the potential Alzheimer's treatment Donanemab, investors should exercise caution when considering the stock at its current price.

This is where Novo Nordisk enters the picture. Focused on the diabetes and obesity fields, the company offers a more attractive investment proposition. Despite being almost as large as Eli Lilly with a market cap of $460 billion, Novo Nordisk presents critical differences that make it a compelling option.

From a valuation perspective, Novo Nordisk appears to be a better deal for investors. With a forward price-to-earnings (P/E) ratio of 38 and a price-to-earnings growth (PEG) ratio of 2.1, it offers better value for expected growth compared to Eli Lilly. Although Novo Nordisk's growth rate may be slightly slower than Eli Lilly's (reflected in its PEG ratio above 4), the stock still presents a more favorable valuation.

Additionally, Novo Nordisk demonstrates a significantly higher return on invested capital (ROIC) than Eli Lilly. With an average ROIC of 73% over the past decade, compared to Eli Lilly's 18%, Novo Nordisk proves to be more effective at generating profits relative to the capital invested. This consistent high ROIC is a positive indicator of the company's ability to create long-term value for shareholders.

One area where Novo Nordisk shines is in its leading GLP-1 product line. GLP-1 drugs, used for weight management and treating Type 2 diabetes, have gained substantial attention in the healthcare industry. Given the growing obesity rate, weight management presents a significant pharmaceutical opportunity, and Novo Nordisk is well-positioned to benefit from this trend.

Furthermore, an analyst from BMO Capital Markets estimates that the market for GLP-1 drugs could reach $100 billion by 2035, providing a substantial growth opportunity for Novo Nordisk as the market leader.

While Novo Nordisk may not have been included in The Motley Fool Stock Advisor's list of top 10 stocks to buy, it's important to consider the company's strong prospects independently. This article highlights the potential upside offered by Novo Nordisk's leadership in the GLP-1 market, appealing valuation, and superior return on capital.

In conclusion, for investors seeking an alternative to Eli Lilly, Novo Nordisk presents a compelling investment opportunity. With its focus on the diabetes and obesity fields, a more favorable valuation, and a track record of generating higher returns on invested capital, Novo Nordisk is well-positioned to deliver long-term growth and outperform its pharmaceutical peers.